NCT05093608 SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma Status TERMINATED Phase PHASE1
NCT05087992 A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers Status COMPLETED Phase PHASE1
NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors Status TERMINATED Phase PHASE1
NCT05070104 CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer Status WITHDRAWN Phase PHASE1
NCT05068206 A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx Status UNKNOWN Phase PHASE2
NCT05065021 Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor Status RECRUITING Phase PHASE2
NCT05063552 Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Status ACTIVE_NOT_RECRUITING Phase PHASE2/PHASE3
NCT05062317 ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases Status RECRUITING Phase PHASE2
NCT05044871 Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer Status COMPLETED Phase PHASE2
NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT05029882 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05022927 A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05009082 Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Status RECRUITING Phase PHASE3
NCT05009017 Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients Status UNKNOWN Phase N/A
NCT05007132 Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Status RECRUITING Phase PHASE2
NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Status COMPLETED Phase PHASE2
NCT05005403 Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan Status RECRUITING Phase PHASE1
NCT05001880 Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Status RECRUITING Phase PHASE2
NCT04988607 Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC Status UNKNOWN Phase PHASE2